348 related articles for article (PubMed ID: 32986848)
1. Development of cannabidiol as a treatment for severe childhood epilepsies.
Williams CM; Stephens GJ
Br J Pharmacol; 2020 Dec; 177(24):5509-5517. PubMed ID: 32986848
[TBL] [Abstract][Full Text] [Related]
2. Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
Lattanzi S; Trinka E; Striano P; Rocchi C; Salvemini S; Silvestrini M; Brigo F
CNS Drugs; 2021 Mar; 35(3):265-281. PubMed ID: 33754312
[TBL] [Abstract][Full Text] [Related]
3. Use of cannabidiol in the treatment of epilepsy.
Mazurkiewicz-Bełdzińska M; Zawadzka M
Neurol Neurochir Pol; 2022; 56(1):14-20. PubMed ID: 35211946
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies.
Reddy DS
Exp Neurol; 2023 Jan; 359():114237. PubMed ID: 36206806
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A;
Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
[TBL] [Abstract][Full Text] [Related]
6. Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
Lattanzi S; Trinka E; Russo E; Striano P; Citraro R; Silvestrini M; Brigo F
Drugs Today (Barc); 2019 Mar; 55(3):177-196. PubMed ID: 30938373
[TBL] [Abstract][Full Text] [Related]
7. Source of cannabinoids: what is available, what is used, and where does it come from?
Specchio N; Pietrafusa N; Cross HJ
Epileptic Disord; 2020 Jan; 22(S1):1-9. PubMed ID: 31941643
[TBL] [Abstract][Full Text] [Related]
8. Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome.
Lattanzi S; Zaccara G; Russo E; La Neve A; Lodi MAM; Striano P
Expert Rev Neurother; 2021 Jan; 21(1):99-110. PubMed ID: 33026899
[TBL] [Abstract][Full Text] [Related]
9. Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders.
Golub V; Reddy DS
Adv Exp Med Biol; 2021; 1264():93-110. PubMed ID: 33332006
[TBL] [Abstract][Full Text] [Related]
10. Cannabidiol in the Treatment of Epilepsy.
von Wrede R; Helmstaedter C; Surges R
Clin Drug Investig; 2021 Mar; 41(3):211-220. PubMed ID: 33559102
[TBL] [Abstract][Full Text] [Related]
11. Cannabis for the Treatment of Epilepsy: an Update.
Gaston TE; Szaflarski JP
Curr Neurol Neurosci Rep; 2018 Sep; 18(11):73. PubMed ID: 30194563
[TBL] [Abstract][Full Text] [Related]
12. The proposed mechanisms of action of CBD in epilepsy.
Gray RA; Whalley BJ
Epileptic Disord; 2020 Jan; 22(S1):10-15. PubMed ID: 32053110
[TBL] [Abstract][Full Text] [Related]
13. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.
Hussain SA; Zhou R; Jacobson C; Weng J; Cheng E; Lay J; Hung P; Lerner JT; Sankar R
Epilepsy Behav; 2015 Jun; 47():138-41. PubMed ID: 25935511
[TBL] [Abstract][Full Text] [Related]
14. Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials.
Gunning B; Mazurkiewicz-Bełdzińska M; Chin RFM; Bhathal H; Nortvedt C; Dunayevich E; Checketts D
Acta Neurol Scand; 2021 Feb; 143(2):154-163. PubMed ID: 32969022
[TBL] [Abstract][Full Text] [Related]
15. Cannabinoids in treatment-resistant epilepsy: A review.
O'Connell BK; Gloss D; Devinsky O
Epilepsy Behav; 2017 May; 70(Pt B):341-348. PubMed ID: 28188044
[TBL] [Abstract][Full Text] [Related]
16. The role of cannabinoids in epilepsy treatment: a critical review of efficacy results from clinical trials.
Nabbout R; Thiele EA
Epileptic Disord; 2020 Jan; 22(S1):23-28. PubMed ID: 31916540
[TBL] [Abstract][Full Text] [Related]
17. Epilepsy and cannabidiol: a guide to treatment.
Arzimanoglou A; Brandl U; Cross JH; Gil-Nagel A; Lagae L; Landmark CJ; Specchio N; Nabbout R; Thiele EA; Gubbay O; The Cannabinoids International Experts Panel ;
Epileptic Disord; 2020 Feb; 22(1):1-14. PubMed ID: 32096470
[TBL] [Abstract][Full Text] [Related]
18. Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain.
García-Peñas JJ; Gil Nagel-Rein A; Sánchez-Carpintero R; Villanueva-Haba V
Rev Neurol; 2021 Sep; 73(S01):S1-S8. PubMed ID: 34486101
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs.
Patsalos PN; Szaflarski JP; Gidal B; VanLandingham K; Critchley D; Morrison G
Epilepsia; 2020 Sep; 61(9):1854-1868. PubMed ID: 32918835
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy.
Franco V; Perucca E
Drugs; 2019 Sep; 79(13):1435-1454. PubMed ID: 31372958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
